1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Anti-epileptic Drugs Market
2.3. Global Anti-epileptic Drugs Market, By Drug Class, 2025 (US$ Million)
2.4. Global Anti-epileptic Drugs Market, By Geography, 2025 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2025

3. Anti-epileptic Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Anti-epileptic Drugs Market Vendors
3.2. Strategies Adopted by Anti-epileptic Drugs Market Vendors

4. Anti-epileptic Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Anti-epileptic Drugs Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape

5. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Hydantoin derivatives
5.3.1.1. Phenytoin
5.3.1.2. Fosphenytoin
5.3.2. Iminostilbenes
5.3.2.1. Carbamazepine
5.3.2.2. Oxcarbazepine
5.3.3. Long acting barbiturates
5.3.3.1. Phenobarbitone
5.3.3.2. Methobarbitone
5.3.4. Succinimides
5.3.4.1. Ethosuximide
5.3.4.2. Methsuximide
5.3.4.3. Phensuximide
5.3.5. Benzodiazepines
5.3.5.1. Clonazepam
5.3.5.2. Nitrazepam
5.3.5.3. Diazepam
5.3.6. Carbonic anhydrase inhibitors (CAI)
5.3.6.1. Acetazolamide
5.3.6.2. Sulthiame
5.3.7. GAMA- vinyl – GABA
5.3.7.1. Vigabatrin
5.3.8. Amino acid derivatives
5.3.8.1. GABA pentin
5.3.9. Monosaccharide derivatives
5.3.9.1. Topiramate
5.3.10. Others

6. North America Anti-epileptic Drugs Market, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
6.3. Anti-epileptic Drugs Market: By Region, 2024-2034, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)

7. UK and European Union Anti-epileptic Drugs Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
7.3. Anti-epileptic Drugs Market: By Region, 2024-2034, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.5. France
7.3.1.5.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)

8. Asia Pacific Anti-epileptic Drugs Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
8.3. Anti-epileptic Drugs Market: By Region, 2024-2034, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.3. India
8.3.1.3.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)

9. Latin America Anti-epileptic Drugs Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
9.3. Anti-epileptic Drugs Market: By Region, 2024-2034, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)

10. Middle East and Africa Anti-epileptic Drugs Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
10.3. Anti-epileptic Drugs Market: By Region, 2024-2034, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Anti-epileptic Drugs Market: By Drug Class, 2024-2034, USD (Million)

11. Company Profile
11.1. Abide Therapeutics (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Advicenne Pharma SA
11.3. Alexza Pharmaceuticals
11.4. Argentum Pharmaceuticals
11.5. GlaxoSmithKline (GSK) plc
11.6. GW Pharmaceuticals Plc
11.7. Janssen Pharmaceuticals
11.8. Marinus Pharmaceuticals
11.9. Novartis Pharmaceuticals Corp
11.10. Otsuka Pharmaceuticals
11.11. Pfizer Inc.
11.12. Takeda Pharmaceutical Company Ltd
11.13. UCB Pharma